Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases.

类风湿性关节炎、牛皮癣和克罗恩病等人体免疫系统失灵引起的疾病在所有文化和社会中都会引起疾病，并给卫生保健提供者带来经济压力。目前的治疗方法依赖于阻断体内炎症介质的生物制药，或者使用抗炎药物等药物；这两种治疗方法都可能有严重的副作用。Cpn10在保持免疫功能以对抗感染的同时，抑制身体的炎症反应。该项目寻求开发基于Cpn10的新的、安全有效的生物药物，用于治疗各种慢性炎症性疾病和自身免疫性疾病。

Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory drugs; both these treatments may have serious side effects. Cpn10 suppresses the body's inflammatory response while maintaining immune function to combat infections. The project seeks to develop new, safe and effective biopharmaceuticals based on Cpn10 for the treatment of a variety of chronic inflammatory diseases and autoimmune disorders.